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A B S T R A C T
FCHL (familial combined hyperlipidaemia) is a highly prevalent genetic lipid disorder that accounts
for a substantial number of premature cardiovascular events. To date, FCHL has been compli-
cated by the different lipid phenotypes that are present within one family and one individual
patient over time. In the present study, we hypothesized that a parabolic relationship between
plasma triacylglycerols (triglycerides) and LDL (low-density lipoprotein)-cholesterol can explain
this so-called ‘multiple-type hyperlipidaemia’ in FCHL. Our hypothesis was tested in two well-
documented FCHL cohorts [Maastricht (n= 145) and Nijmegen (n= 299)] that were followed
over a 5-year interval. Three groups were constructed depending on plasma triacylglycerols: group
A (individuals with both measurements below 1.5 mmol/l), group B (one measurement below and
one measurement above 1.5 mmol/l) and group C (both measurement above 1.5 mmol/l). In both
male, but not female, cohorts, a significant positive relationship between plasma triacylglycerols
and LDL-cholesterol was observed in group A (P= 0.02 for Maastricht cohort and P= 0.001
for the Nijmegen cohort), a significant negative relationship in group C (P= 0.01 for Maastricht
cohort and P= 0.02 for the Nijmegen cohort), and a relationship intermediate to group A and C
in group B. In contrast, both apoB (apolipoprotein B) levels and the prevalence of cardiovascular
disease were related with plasma triacylglycerols in a more linear fashion. In conclusion, a parabolic
relationship between plasma triacylglycerols and LDL-cholesterol explains the ‘multiple-type
hyperlipidaemia’ in FCHL. In addition, the linear relationship between triacylglycerols and
both apoB levels and the prevalence of cardiovascular disease substantiate the use of apoB
instead of LDL-cholesterol in the diagnosis of FCHL and the prediction of cardiovascular
disease.
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INTRODUCTION
Almost 30 years ago, Goldstein et al. [1] were the first to
delineate FCHL (familial combined hyperlipidaemia) as a
genetic hyperlipidaemia.Nowadays, it is well-established
that in Western societies FCHL is a highly prevalent
disease (1 in 100) with an approx. 5-fold increased risk of
premature cardiovascular complications [1,2]. It has been
estimated that 10% of patients with premature coronary
artery disease are affected by FCHL [1]. Many patients
with FCHL have features of the metabolic syndrome,
such as insulin resistance [3], visceral obesity [2,4],
fatty liver [5,6], low HDL (high-density lipoprotein)-
cholesterol and high BP (blood pressure) [7]. With
the current epidemic of obesity, it is expected that the
prevalence of the metabolic syndrome, and hence FCHL,
will increase even further with a subsequent increase in
the incidence of cardiovascular complications.
Despite the progressive insights into the clinical syn-
drome, several important questions around FCHL
remain. One of the most challenging is the puzzle
of the different plasma lipid phenotypes observed in
relatives in families with FCHL, or even more confusing
within one patient with FCHL [1,8], i.e. hyperchol-
esterolaemia, hypertriglyceridaemia or the combination
of both. This phenomenon is called the ‘multiple-type
hyperlipidaemia’ and it has resulted in the requirement
that an elaborate diagnostic procedure in several relatives
is needed to robustly establish FCHL in a family and
subsequently in one patient with FCHL. Furthermore,
once a subject is diagnosed as ‘affected’, he or she
might be non-affected at the next visit due to the same
phenomenon. Efforts have therefore been made to
circumvent this problem by redefining FCHL with
parameters that are more specific and more stable over
time, such as apoB (apolipoprotein B) [9,10].
Previous studies by Veerkamp and co-workers [11,12]
have demonstrated that the switch in triacylglycerol
(triglyceride) phenotype, i.e. from normotriglycerid-
aemia to hypertriglyceridaemia or vice versa, is associated
with changes in BMI (body mass index) and insulin
resistance in FCHL. More recently, another metabolic
factor, i.e. hepatic fat as reflected by plasma alanine
aminotransferase levels, was added to this list in a second
Dutch FCHL cohort [13]. As the metabolic pathways
contributing to the switch in triacylglycerol phenotype
are being elucidated, no factors have yet been linked to
the switch in cholesterol phenotype. In the present study,
we anticipated that the switch in cholesterol phenotype
depends on changes in plasma triacylglycerols.
Careful study of kinetic data on synthesis and meta-
bolism of lipoprotein particles, as reviewed by Packard
and Shepherd [14], has led us to hypothesize that plasma
triacylglycerols and LDL (low-density lipoprotein)-
cholesterol levels are part of a metabolic continuum that
follows a parabolic relationship, i.e. at low triacylglycerol
levels (below 1.5 mmol/l), LDL-cholesterol increases in
parallel with increasing triacylglycerols levels, whereas a
further increase in triacylglycerols above the triacylgly-
cerol cut-off of 1.5 mmol/l is associated with a decline
in LDL-cholesterol. This complex relationship would be
due to the secretion of different species of VLDL (very-
LDL) particles by the liver, i.e.VLDL2 and triacylgly-
cerol-rich VLDL1. Since VLDL2 particles, which are
mainly catabolized into LDL particles, are secreted
when plasma triacylglycerols are low [14], a positive
relationship between plasma triacylglycerols and LDL-
cholesterol can be anticipated when plasma triacylglycer-
ols are below 1.5 mmol/l. In contrast, when plasma tri-
acylglycerols increase, VLDL1 particles become abund-
ant, which are not all catabolized into LDL particles
[14]. Furthermore, these LDL particles are cholesterol-
depleted due toCETP (cholesteryl ester transfer protein)-
mediated cholesteryl ester exchange with VLDL1
particles [14]. As a consequence, we hypothesized that, at
high triacylglycerols (above 1.5 mmol/l), the relationship
between plasma triacylglycerols and LDL-cholesterol is
negative (see Figure 1 for a detailed explanation).
A parabolic relationship between plasma triacylglycer-
ols and LDL-cholesterol could theoretically account for
the switch in cholesterol phenotype in FCHL. Therefore,
in the present study, we investigated the presence of
such a parabola in two previously reported well-defined
FCHL cohorts that have been followed over time, i.e.
the Maastricht and Nijmegen FCHL cohorts [11,13].
In addition, we studied the longitudinal relationship
between plasma triacylglycerols and apoB, hallmarks
of FCHL, and the prevalence of CVD (cardiovascular
disease), the clinically relevant end point of FCHL.
MATERIALS AND METHODS
Study populations
Family members with FCHL were collected and fol-
lowed prospectively in two cohorts: the Maastricht
and Nijmegen cohorts. The Maastricht pedigrees with
FCHL (n= 145 subjects) were originally recruited based
on the cut-off values of 6.5 mmol/l and/or 2.3 mmol/l
for plasma cholesterol and triacylglycerols respectively.
Their baseline (1999) and follow-up (2004) characteristics
have recently been described in detail [13]. TheNijmegen
familieswith FCHL (n= 299 subjects) were originally re-
cruited based on the 90th percentile diagnostic criteria for
hypercholesterolaemia and hypertriglyceridaemia, which
has been described in detail elsewhere, together with their
baseline (1994) and follow-up (1999) characteristics [11].
In both cohorts, Type 2 diabetes mellitus was an exclu-
sion criterion for the index patient (=proband) [7,11].No
subjects carried the apoE2/E2 genotype. Furthermore,
patients with FCHL were withdrawn from lipid-lower-
ing medication for at least 2 weeks prior to both visits.
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The presence of CVD was defined by angina pectoris,
myocardial infarction, stroke, peripheral vascular disease
or vascular surgery.
The studies were approved by the Ethics Committee
of the University Medical Center Nijmegen and the
University Hospital Maastricht/Maastricht University.
All subjects gave written informed consent.
Measurements
Subjects visited the study centres after an overnight
fast. Weight and height were measured with participants
wearing light clothing only, and the BMI was calculated
as weight divided by height squared (kg/m2).
Fasting plasma triacylglycerols, total cholesterol,
HDL-cholesterol and apoBwere determined as described
previously [7,11,15]. LDL-cholesterol was calculated
with the Friedewald formula [LDL-cholesterol=
total cholesterol−HDL-cholesterol−(plasma triacylgly-
cerols× 0.45)] [16]. As this formula is only valid for
plasma triacylglycerols <4.5 mmol/l [16], subjects with
triacylglycerol levels above this value were excluded
from analyses (six subjects from the Maastricht cohort
and seven subjects from theNijmegen study population).
In the Nijmegen FCHL cohort, LDL-cholesterol was
also approximated by subtracting VLDL-cholesterol and
HDL-cholesterol from total cholesterol levels. VLDL-
cholesterol was measured by ultracentrifugation [9].
Statistical analyses
Baseline characteristics of the cohorts are presented
as means+− S.D. or medians (interquartile range). A
Student’s t test was used to detect differences in age be-
tween FCHL probands (= index patient of one pedigree
with FCHL) and their relatives, and between the
Maastricht and Nijmegen probands/relatives. The anth-
ropometric and lipid parameters were compared by
linear regression with the inclusion of age and sex.
To test the possibility of a parabolic relationship
between plasma concentrations of triacylglycerols and
LDL-cholesterol as an explanation for the ‘multiple-type
hyperlipidaemia’ in FCHL, three groups were defined
(Figure 1): a group with plasma triacylglycerols below
1.5 mmol/l both at baseline and at follow-up (group A),
a group with triacylglycerols above 1.5 mmol/l at both
time points (group C), and the remaining group in whom
plasma triacylglycerols were below 1.5 mmol/l at one
time-point and above 1.5 mmol/l at the other moment
(groupB). The cut-off value of 1.5 mmol/lwas used as it is
commonly accepted that from this value there is substan-
tial cholesteryl ester exchange between VLDL1 and LDL
particles (Figure 1) [14]. As sex hormones are known to
influence lipidmetabolism [17], all analyseswere conduc-
ted formale and female subjects separately.Amixed linear
model for repeated measurements with a random inter-
cept was used accounting for repeated measurements in
one individual.A significant relationship should therefore
Figure 1 Hypothesized parabolic relationship between
plasma triacylglycerols and LDL-cholesterol
In normotriglyceridaemic conditions, triacylglycerols are mainly incorporated in
VLDL2 particles, which are mostly degraded into LDL particles. Therefore an
increase in VLDL2 particles is expected to lead to an increase in plasma
triacylglycerols (TGs) and LDL-cholesterol, explaining part A of the parabolic
curve in (b). A further increase in plasma triacylglycerols is accompanied by
an increased secretion of triacylglycerol-rich VLDL1 particles. VLDL1 particles
exchange cholesteryl ester (CE) and triacylglycerols with LDL (and HDL) particles,
mediated by CETP, resulting in cholesterol-depleted LDL particles. Many cholesteryl
esters transferred to VLDL1 particles leave the plasma cholesterol pool, since it
is estimated that a large proportion of the VLDL1 particles is not catabolized
into VLDL2 and eventually to LDL, but is directly taken up as VLDL remnants
by, among others, the liver. This would explain the negative correlation between
plasma triacylglycerols and LDL-cholesterol (part C of the parabolic curve in b).
Part B of the parabolic curve in (b) depicts the transition from VLDL2 secretion
to VLDL1 secretion by the liver. This occurs, on average, at plasma triacylglycerols
of 1.5 mmol/l. The three dashed lines in (b) indicate the three subgroups that
have been constructed to test our hypothesis of a parabolic relationship (see the
Materials and methods section). IDL, intermediate-density lipoprotein.
be interpreted as the intra-individual relationship aver-
aged for all subjects in the particular subgroup.According
to our hypothesis, we anticipated a significant positive re-
lationship in group A, a significant, negative relationship
in group C and a relationship intermediate to groups A
and C in group B (Figure 1). In addition, the regression
slopes of the different subgroups were compared with
each other by using interaction terms. All analyses were
conducted with SPSS 13.0 statistical package (SPSS Inc.).
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Table 1 Baseline characteristics of probands and relatives with FCHL in the Maastricht and Nijmegen cohorts
Values are means+− S.D., or medians (interquartile range). Values in square brackets indicate males and females respectively. All analyses were Hochberg corrected.
∗P < 0.05 compared with relatives, as determined using a Student’s t test; †P < 0.05 compared with the Maastricht relatives, age- and sex-corrected; ‡P < 0.05
compared with the Maastricht probands, age- and sex-corrected.
Maastricht FCHL cohort Nijmegen FCHL cohort
Characteristic Relatives Probands Relatives Probands
Male/female (n) 50/68 8/13 115/147 19/11
Age (years) 41.1+− 15.8 52.3+− 11.1∗ 38.2+− 15.8 48.9+− 16.4∗
BMI (kg/m2) 25.8+− 4.2 28.5+− 4.3 23.9+− 3.5† 25.3+− 4.2‡
Total cholesterol (mmol/l) 5.4+− 1.2 6.4+− 1.1 5.6+− 1.3† 6.3+− 1.3
Triacylglycerols (mmol/l) 1.2 (0.9–1.7) 2.1 (1.3–2.4)∗ 1.4 (0.8–1.8) 2.1 (1.6–3.0)∗
ApoB (g/l) 1.1+− 0.3 1.4+− 0.2∗ 1.1+− 0.3 1.3+− 0.3
HDL-cholesterol (mmol/l) 1.0+− 0.2 [0.8/1.0] 0.9+− 0.3 [0.9/0.9] 1.2+− 0.3 [1.1/1.3]† 1.0+− 0.3 [0.9/1.2]
LDL-cholesterol (mmol/l) 3.9+− 1.1 4.6+− 1.2 3.7+− 1.2 4.3+− 1.3
CVD (%) 11 [15/8] 33 [42/27] 11 [16/7] 37 [62/5]
RESULTS
Baseline characteristics of Maastricht and
Nijmegen FCHL study populations
Baseline characteristics of Maastricht and Nijmegen
FCHL probands and their relatives are shown in Table 1.
Maastricht and Nijmegen probands with FCHL were
significantly older when compared with their relatives.
The seemingly marked difference in total cholesterol
levels between probands with FCHL and relatives was
lost after correction for age and sex (P= 0.07 for the
Maastricht cohort and P= 0.32 for Nijmegen cohort).
In contrast, age- and sex-adjusted analyses revealed
that probands with FCHL still had significantly higher
plasma triacylglycerols (Table 1).
Probands and relatives in the Maastricht population
were significantly more obese than in the Nijmegen
FCHL cohort (Table 1). Furthermore, small, but signi-
ficant, differences were observed for plasma total chol-
esterol and HDL-cholesterol levels between the
Maastricht and Nijmegen relatives with FCHL.
As reported previously [11,13], the proportion of
subjects who switched lipid phenotype during follow-up,
i.e. from normotriglyceridaemia to hypertriglycerid-
aemia, from normocholesterolaemia to hyperchole-
sterolaemia or vice versa, was similar in both cohorts
(30% and 28% in the Maastricht and Nijmegen
cohorts respectively).
Longitudinal parabolic relationship
between plasma triacylglycerols and
LDL-cholesterol
A possible parabolic relationship between plasma
triacylglycerols and LDL-cholesterol, to explain the
‘multiple-type hyperlipidaemia’ in FCHL, was first eval-
uated in males with FCHL from both study populations.
As shown in Figure 2(a), mixed linear regression analysis
revealed a 5-year positive relationship between plasma
triacylglycerols and LDL-cholesterol forMaastricht men
with FCHL in group A (plasma triacylglycerols below
1.5 mmol/l at both time points; P= 0.02) and group B
(plasma triacylglycerols below and above 1.5 mmol/l
at different time points; P= 0.2). This relationship was
significant, but negative, for men in group C (plasma
triacylglycerols above 1.5 mmol/l at both time points;
P= 0.01). According to our hypothesis, the slopes of
the regression lines, indicated as β, decreased with
increasing plasma triacylglycerols (βA = 1.8, βB = 0.3 and
βC =−0.7; Figure 2a). Furthermore, these slopes were all
significantly different fromeach other (βA comparedwith
βB, P= 0.02; βB compared with βC, P= 0.003; and βA
compared with βC, P< 0.001; Hochberg corrected).
Comparable results were obtained in the male Nijmegen
cohort (Figure 2b). Of additional interest, very similar
results were obtained when LDL-cholesterol levels,
approximated by subtracting VLDL-cholesterol and
HDL-cholesterol from total cholesterol levels, were
taken for analysis (Figure 2b, inset). Therefore the use
of the Friedewald formula does not account for the
observed parabola.
The results for the female Maastricht and Nijmegen
FCHL cohorts were less consistent: despite a trend
towards a parabolic relationship in the Maastricht cohort
(βA = 0.6, P= 0.02; βB = 0.5, P= 0.2; and βC =−0.3,
P= 0.1), no significant relationship was observed in any
subgroup of the Nijmegen cohort (βA =−0.1, P= 0.5;
βB =−0.2, P= 0.3; and βC = 0.01, P= 0.9).
Parabolic relationship between plasma
triacylglycerols and LDL-cholesterol
within individual male patients
with FCHL
Further evidence for the longitudinal relationship
between plasma triacylglycerols and LDL-cholesterol
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Figure 2 5-Year intra-individual relationship between
plasma triacylglycerols and LDL-cholesterol in male
Maastricht (a) and Nijmegen (b) FCHL cohorts
(a) Maastricht cohort: group A (n = 19), βA = 1.8, P = 0.02; group B
(n = 19), βB = 0.3, P = 0.2; group C (n = 20), βC =−0.7, P = 0.01.
(b) Nijmegen cohort: group A (n = 46), βA = 1.0, P = 0.001; group B
(n = 37), βB = 0.2, P = 0.3; group C (n = 51), βC =−0.2, P = 0.02.
The inset in (b) shows the results for LDL-cholesterol approximated by subtracting
VLDL-cholesterol and HDL-cholesterol from total cholesterol in the Nijmegen FCHL
population. Regression lines are drawn from the minimum to the maximum
triacylglycerols value of each subgroup.
in the male FCHL population described above was
assessed by investigating whether one individual can
pass completely through the parabolic curve. For this, at
least three consecutive measurements in one individual
were required with plasma triacylglycerols values below,
around and above the parabolic peak value of 1.5 mmol/l.
Although such series of data are hard to obtain for
each individual, 13 male subjects in the combined
study population were measured more than twice and
fulfilled each of the following plasma triacylglycerols
criteria: one measurement around 1.5 mmol/l, i.e.
between the arbitrary values of 1.4 and 1.6 mmol/l, one
measurement below 1.4 mmol/l and one measurement
above 1.6 mmol/l. Of the 13 subjects who met these
criteria, 11 subjects had an increase in LDL-cholesterol
levels when plasma triacylglycerol values increased from
low to moderate levels, whereas a further increase
was accompanied with a decrease in LDL-cholesterol
(Figure 3).
Longitudinal relationship between plasma
triacylglycerols and apoB and the
prevalence of CVD
As elevated apoB levels, the equivalent of the amount of
atherogenic particles in plasma, are a hallmark of FCHL,
we subsequently analysed the longitudinal relationship
between plasma triacylglycerols and apoB in the male
Maastricht and Nijmegen FCHL cohorts. Of interest, no
parabolic relationship was observed. At the lower plasma
triacylglycerol range, both cohorts had an increase
in apoB with increasing triacylglycerols, which was
significant for the Nijmegen cohort (βA = 0.2, P< 0.001),
but not for theMaastricht population (βA = 0.3, P= 0.10)
(Figures 4a and 4b). A further increase in plasma tri-
acylglycerols was not associated with a decrease in
plasma apoB levels in either of the cohorts (Figures 4a
and 4b), in contrast with what has been observed
for LDL-cholesterol. As a consequence, the LDL-
cholesterol:apoB ratio, which is indicative of LDL
particle size, did decrease with increasing plasma
triacylglycerols (P< 0.001 for group C in both the
Maastricht and Nijmegen cohorts; Figures 4a and
4b, insets). When both male FCHL cohorts were
combined to analyse the prevalence of CVD in the three
triacylglycerols subgroups, the highest prevalence was
observed in groupC (P= 0.04 for groupCcomparedwith
group B; P= 0.006 for group C compared with group A;
as determined using a logistic regression with correction
for age; Figure 4c). Of note, the significantly increased
prevalence ofCVD in groupCwas similar in both cohorts
(40 and 35% in the Maastricht and Nijmegen cohorts
respectively).
DISCUSSION
It has been estimated that approx. 10% of survivors of a
premature myocardial infarction are affected by FCHL
[1]. FCHL is currently viewed as a genetically complex
disease, implying that multiple genes in combination
with environmental factors are responsible for the
different metabolic pathways that eventually result
in the characteristic hyperlipidaemic phenotype [18].
On top of this complexity, there is the ‘multiple-type
hyperlipidaemia’, i.e. the presence of different lipid
phenotypes within one family and one individual patient
with FCHL, that complicates its diagnosis, research and
treatment. In the present study, we anticipated that a
parabolic relationship between plasma triacylglycerols
andLDL-cholesterol can account for the switch in plasma
cholesterol phenotype in FCHL. This hypothesis was
based on the fact that the liver is able to secrete different
VLDL particles with different catabolic fates, depending
on the actual plasma triacylglycerols concentrations
[14].
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Figure 3 Intra-individual relationship between plasma triacylglycerols and LDL-cholesterol for 13 family members with
FCHL with three consecutive triacylglycerol measurements below 1.4 mmol/l, between 1.4 and 1.6 mmol/l and above
1.6 mmol/l
(a–m) Individual traces for the 13 subjects. Dashed vertical lines indicate plasma triacylglycerol levels of 1.4 and 1.6 mmol/l. (n) The mean relationship, with error
bars representing S.E.M. is shown (analysed with Wilcoxon’s non-parametric test for paired samples).
Our hypothesis was verified in two well-documented
FCHL cohorts that have been followed over time
[11,13]. We demonstrated recently that the switch in lipid
phenotype is very similar in both cohorts [11,13], and we
have shown in the present study that baseline character-
istics of the Maastricht and Nijmegen FCHL cohorts
were comparable with regard to plasma lipid levels and
prevalence of CVD. This provided uswith the unique op-
portunity to test our hypothesis in two comparable, but
independent, FCHL cohorts. Both male Maastricht and
Nijmegen cohorts clearly demonstrated a longitudinal
parabolic relationship between plasma triacylglycerols
and LDL-cholesterol. This relationship was also present
in individual male patients with observations in each
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Figure 4 5-Year intra-individual relationship between
plasma triacylglycerols and apoB levels in male Maastricht
(a) and Nijmegen (b) FCHL cohorts
The insets in (a and b) show the relationship between plasma triacylglycerols
and the LDL-cholesterol:apo B ratio, which is indicative of the LDL particle size.
(c) Relationship of the three triacylglycerols subgroups with the prevalence of
CVD. For this purpose, the male Maastricht and Nijmegen cohorts were combined
to increase statistical power (analysed with logistic regression with correction for
age).
of the different triacylglycerols segments, substantiating
the evidence that one individual can indeed pass
completely through the parabolic curvature. In addition,
this relationship was not simply due to the use of the
Friedewald formula, since similar results were obtained
with an alternative approximation of LDL-cholesterol.
The results in the female cohorts were less consistent,
Figure 5 Conceptual framework of the parabolic relation-
ship between plasma triacylglycerols and LDL-cholesterol
as an explanation for the ‘multiple-type hyperlipidemia’ in
FCHL
The grey-shaded area represents the 95 % confidence interval for the combined
male Maastricht and Nijmegen cohorts. The horizontal and vertical lines indicate
the cut-off values for hypercholesterolaemia (HC) and hypertriglyceridaemia (HTG)
respectively, as defined by the NCEP ATPIII (National Cholesterol Education Program
Adult Treatment Panel III) criteria. NL, normolipidaemia.
which is probably due to the well-known inter- and
intra-individual scattering effects of oestrogens on lipid
levels in a population with different oestrogen levels
[17].
We believe that the present results, combined with our
findings obtained previously, account for the ‘multiple-
type hyperlipidaemia’ in FCHL, as shown in Figure 5. In
previous studies, we have shown that the switch in plasma
triacylglycerols is accompanied by changes in obesity,
insulin resistance and the amount of hepatic fat [11–13].
As these metabolic factors cause a switch in plasma
triacylglycerols, they automatically induce changes in
plasma LDL-cholesterol and, when substantial, cause a
switch in cholesterol phenotype.
A striking observation in the present study is the
absence of a parabolic, and the presence of an almost
linear, relationship between plasma triacylglycerols
and the amount of atherogenic particles in plasma, as
reflected by apoB levels. This observation is pivotal in
several respects. First, given the fact that the majority
of the plasma apoB is accounted for by LDL particles
[19], the discrepancy between the curves for LDL-chole-
sterol and apoB is most probably explained by a change
in LDL particle composition, i.e. the development of
small-dense LDL, as shown by a decrease in the LDL-
cholesterol:apoB ratio. This finding is in concordance
with our hypothesis. Secondly, although the parabolic
relationship for LDL-cholesterol offers an explanation
for the multiple-type hyperlipidaemia in FCHL, the
linear relationship for apoBmay serve as a solution for the
accompanying diagnostic difficulties, since it is expected
that apoB levels switch less frequently from normal to
C© The Authors Journal compilation C© 2008 Biochemical Society
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abnormal over time. Indeed, many reports have shown
a lower temporal variability for apoB levels and have
therefore advocated the use of apoB instead of cholesterol
levels in diagnosing FCHL [9,10,20,21]. Lastly, and most
importantly, the present study suggests that apoB levels
are superior to LDL-cholesterol in predicting cardio-
vascular events, at least in hypertriglyceridaemic patients
with FCHL, since the relationship between plasma tri-
acylglycerols and the prevalence of CVD was also
linear. Again, it is anticipated that the presence of small-
dense LDL particles, which are more atherogenic than
buoyant LDL particles [22,23], is responsible for this dis-
crepancy. These findings corroborate the use of apoB
in the ongoing debate of LDL-cholesterol compared
with apoB levels in predicting cardiovascular events
[24].
In summary, the present 5-year follow-up study in two
well-documented FCHL cohorts has demonstrated that
plasma triacylglycerols and LDL-cholesterol are related
in a parabolic fashion in male family members with
FCHL. These findings account for the ‘multiple-type
hyperlipidaemia’ in FCHL and, therefore, improve our
understanding of the natural history of this highly pre-
valent disease. Furthermore, the more linear relationship
between plasma triacylglycerols and both apoB levels
and the prevalence of CVD may provide a solution to
this complex phenomenon, and advocates further the use
of apoB instead of LDL-cholesterol levels in the diag-
nosis of FCHL and the prediction of cardiovascular
complications.
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